Methylphenidate extended-release orally disintegrating tablets (Cotempla XR-ODT™) in attention-deficit hyperactivity disorder in children aged 6‒17 years: a profile of their use

<div>Compliance with ethical standards</div><div><i><br></i></div><div><i>Funding:</i> The preparation of this review was not supported by any external funding.</div><div><br></div><div><i>Conflicts of interest:</i> K.A. Lyseng-Williamson is a employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.</div><div><br></div><div>Additional information about this Adis Drug Review can be found <b><a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews">here</a>.</b></div><div><br></div><div>Abstract</div><div><br></div><div>The extended-release orally disintegrating tablet (XR-ODT) formulation of methylphenidate (Cotempla XR-ODT™) is an effective and generally well-tolerated option for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adolescents. Because of the pharmacokinetic profile of this formulation, methylphenidate XR-ODT is administered once daily. As methylphenidate XR-ODT comprise both immediate- and extended-release methylphenidate particles, its use may be of particular benefit in individuals who require a rapid onset (clinical improvements are shown within 1 h) and prolonged reduction in ADHD symptoms (clinical improvements are maintained for 12 h). The XR-ODT formulation of methylphenidate allows relatively easy administration (the ODT dissolves rapidly on the tongue, followed by swallowing of the disintegrated particles with saliva without the need for water), which may be of particular benefit in children and adolescents who have difficulty swallowing tablets or capsules.</div><div>Access to the full article can be found <b><a href="https://link.springer.com/article/10.1007/s40267-017-0462-2">here</a>.</b></div><div><br></div><div>© Springer International Publishing AG, part of Springer Nature 2017